About this Journal Submit a Manuscript Table of Contents
Disease Markers
Volume 19 (2004), Issue 4-5, Pages 229-238
http://dx.doi.org/10.1155/2004/759530

SELDI-TOF Serum Profiling for Prognostic and Diagnostic Classification of Breast Cancers

Christine Laronga,2 Stephen Becker,2 Patrice Watson,3 Betsy Gregory,1 Lisa Cazares,1 Henry Lynch,3 Roger R. Perry,2 George L. Wright Jr.,1 Richard R. Drake,1 and O. John Semmes1

1Departments of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, Virginia and the Virginia Prostate Center, Norfolk, VA, USA
2Department of Surgery, Eastern Virginia Medical School, Norfolk, Virginia and the Virginia Prostate Center, Norfolk, VA, USA
3Department of Preventive Medicine, Creighton University, Omaha, NE, USA

Received 13 July 2004; Accepted 13 July 2004

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry has emerged as a successful tool for serum based detection and differentiation of many cancer types, including breast cancers. In this study, we have applied the SELDI technology to evaluate three potential applications that could extend the effectiveness of established procedures and biomarkers used for prognostication of breast cancers. Paired serum samples obtained from women with breast cancers prior to surgery and post-surgery (6–9 mos.) were examined. In 14/16 post-treatment patients, serum protein profiles could be used to distinguish these samples from the pre-treatment cancer samples. When compared to serum samples from normal healthy women, 11 of these post-treatment samples retained global protein profiles not found in healthy women, including five low-mass proteins that remained elevated in both pre-treatment and post-treatment serum groups. In another pilot study, serum profiles were compared for a group of 30 women who were known BRCA-1 mutation carriers, half of whom subsequently developed breast cancer within three years of the sample procurement. SELDI protein profiling accurately classified 13/15 women with BRCA-1 breast cancers from the 15 non-cancer BRCA-1 carriers. Additionally, the ability of SELDI to distinguish between the serum profiles from sentinel lymph node positive and sentinel lymph node negative patients was evaluated. In sentinel lymph node positive samples, 22/27 samples were correctly classified, in comparison to the correct classification of 55/71 sentinel lymph node negative samples. These initial results indicate the utility of protein profiling approaches for developing new diagnostic and prognostic assays for breast cancers.